Why the study?
Telmisartan has unique pharmacologic properties, but its comparative effectiveness against other ARBs in real-world populations remains unclear.
Does telmisartan reduce stroke, heart failure, and all-cause mortality in hypertensive patients aged 55-85 years compared to other ARBs?
Does telmisartan reduce stroke, heart failure, and all-cause mortality in hypertensive patients aged 55-85 years compared to other ARBs?
In a large real-world cohort, telmisartan was associated with significantly lower risks of stroke, heart failure, and all-cause mortality compared to other ARBs in hypertensive patients.
Introduction: Telmisartan is a long-acting angiotensin II receptor blocker (ARB) with unique pharmacologic properties, including partial PPAR-γ activation. Its comparative effectiveness against other ARBs in real-world populations remains unclear. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, including hypertensive patients aged 55-85 years without prior stroke, heart failure, or myocardial infarction. After 1:1 propensity score matching, 41,598 patients were included in each group. Results: Telmisartan use was associated with a significantly lower risk of stroke (HR 0.805, 95% CI 0.751-0.863), heart failure (HR 0.75, 95% CI 0.672-0.836), and all-cause mortality (HR 0.59, 95% CI 0.542-0.642) compared to other ARBs. Subgroup analyses showed consistent benefits across sex, diabetes, chronic kidney disease, and hyperlipidemia. Conclusions: In this large real-world matched cohort of over 83,000 patients, telmisartan was associated with superior cardiovascular and cerebrovascular outcomes compared to other ARBs, supporting its potential as a preferred antihypertensive agent in high-risk populations.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: